FDA Approves RADIESSE Injectable for Décolleté Wrinkles
Overview
RADIESSE dermal filler has received FDA approval for treating wrinkles in the décolleté area in patients aged 22 and older. Clinical data demonstrate high patient satisfaction and visible skin improvement lasting up to 2 years.
Background
RADIESSE is a biostimulatory dermal filler that promotes collagen, elastin, and other structural proteins essential for dermal integrity. Previously approved for facial and body use, it now has an additional indication for décolleté wrinkle treatment. The product has been evaluated extensively in over 250 scientific publications and is widely used worldwide. Its mechanism involves jump-starting the skin’s regenerative process to improve firmness and smoothness without surgery.
Data Highlights
Outcome
Percentage
Patient satisfaction with skin tightness
80%+
Likelihood to undergo repeat treatment after >1 year
83%
Interest in additional RADIESSE treatments
93%
Healthcare providers observing visible improvement by 4 months
90%
Increase in demand for noninvasive skin-lifting treatments
39%
Key Findings
RADIESSE is FDA-approved for décolleté wrinkle treatment in patients aged 22 years and older.
The injectable stimulates collagen and elastin production, enhancing dermal integrity.
Clinical studies report over 80% patient satisfaction with skin tightness post-treatment.
90% of healthcare providers noted visible improvement within 4 months of treatment.
Adverse events include bruising, redness, swelling, pain, itching, difficulty chewing, and nodules at injection sites.
Serious risks include potential vision abnormalities and stroke from unintentional intravascular injection.
Clinical Implications
RADIESSE offers a non-surgical option for improving décolleté wrinkles with durable effects lasting up to 2 years. Clinicians should carefully screen patients for allergies, bleeding disorders, and contraindications, and counsel them on potential adverse events and rare but serious complications. The treatment may meet growing patient demand for noninvasive skin-lifting procedures.
Conclusion
The FDA approval of RADIESSE for décolleté wrinkles expands therapeutic options for skin rejuvenation in this area, supported by strong patient satisfaction and clinical efficacy data. Proper patient selection and technique are essential to maximize benefits and minimize risks.
References
Merz Aesthetics -- FDA Approval of RADIESSE for Décolleté Wrinkles
